Moody Aldrich Partners LLC Viridian Therapeutics, Inc.\De Transaction History
Moody Aldrich Partners LLC
- $475 Million
- Q4 2024
A detailed history of Moody Aldrich Partners LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Moody Aldrich Partners LLC holds 58,688 shares of VRDN stock, worth $1.07 Million. This represents 0.24% of its overall portfolio holdings.
Number of Shares
58,688Holding current value
$1.07 Million% of portfolio
0.24%Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
187Shares Held
77.7MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$87.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$80.9 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$71.1 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$68.7 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$63.1 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $730M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...